News | May 22, 2022
Karkinos Healthcare receives investment from Mayo Clinic
Investment with representation on the Board of Directors and technical know-how
Investment with representation on the Board of Directors and technical know-how
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Acute therapies continue to report strong growth compared to chronic ones.
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
